Get to know our clinical trials
Phase 2b/3, multi-part, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of atacicept in subjects with IgA nephropathy (IgAN)
EN ESTE ESTUDIO SE COMPARARÁN LOS EFECTOS DEL FÁRMACO DEL ESTUDIO CON UN PLACEBO PARA AVERIGUAR SI EL FÁRMACO DEL ESTUDIO AYUDA A TRATAR LA NIGA. UN PLACEBO TIENE EL MISMO ASPECTO QUE EL MEDICAMENTO DEL ESTUDIO, PERO NO CONTIENE NINGÚN MEDICAMENTO (NINGÚN COMPONENTE ACTIVO). LOS INVESTIGADORES USAN UN PLACEBO PARA COMPROBAR SI UN MEDICAMENTO EN ESTUDIO ES MÁS EFICAZ O ES MÁS SEGURO QUE NO TOMAR NADA EN ABSOLUTO.
Technical Summary
- PHASE 2B/3, MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATACICEPT IN SUBJECTS WITH IGA NEPHROPATHY (IGAN)
- Code EudraCT: 2023-503772-24-00
- Protocol number: VT-001-0050
- Promoter: Vera Therapeutics
- Molecule/Drug: Atacicept
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.